Galapagos reported a challenging third quarter of 2025, marked by the decision to wind down its cell therapy business amid unsuccessful acquisition discussions, while refocusing on core development efforts and potential business opportunities.

• The Board has unanimously agreed to wind down the cell therapy division, impacting approximately 365 employees across several global locations.
• An extensive strategic review yielded no viable proposals for the cell therapy business, prompting the decision to seek alternative paths for value realization.
• The TYK2 program continues to progress, with Phase III enabling studies fully enrolled and data expected by early 2026.
• New board appointments were made to strengthen governance and support the transition towards a focused business development strategy.